Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 928, Issue , 2013, Pages 52-57

  Jia, Mengmeng ^a   Li, Jie ^a   He, Xiaomeng ^a   Liu, Mingzhou ^b   Zhou, Ying ^a   Fan, Yue ^c   Li, Weiyong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN POLYTECHNIC UNIVERSITY   (China)

^c HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Iloperidone; LC MS MS; Metabolites; Pharmacokinetic

Indexed keywords

ILOPERIDONE; LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID-LIQUID EXTRACTION; MULTIPLE-REACTION MONITORING MODES; PIOGLITAZONE HYDROCHLORIDES; SIMULTANEOUS DETERMINATIONS; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PHARMACOKINETICS; PLASMA (HUMAN);

BIOMOLECULES;

ACETIC ACID ETHYL ESTER; ACETONITRILE; AMMONIUM FORMATE; FORMIC ACID; ILOPERIDONE; PIOGLITAZONE;

ACCURACY; ADULT; ARTICLE; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; EXTRACTION; FLOW RATE; HUMAN; HUMAN EXPERIMENT; LIQUID; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; METABOLITE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; TEMPERATURE; VALIDATION STUDY;

ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; ISOXAZOLES; LIQUID-LIQUID EXTRACTION; MALE; PIPERIDINES; RECEPTORS, DOPAMINE D2; SENSITIVITY AND SPECIFICITY; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; TANDEM MASS SPECTROMETRY;

EID: 84876738988     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.03.026     Document Type: Article

References (16)

1. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Brain Res. 2002, 956:349.
2. Kalkman H.O., Subramanian N., Hoyer D. Neuropsychopharmacology 2001, 25:904.
3. Kalkman H.O., Feuerbach D., Lötscher E., Schoeffter P. Life Sci. 2003, 73:1151.
4. Kongsamut S., Roehr J.E., Cai J., Hartman H.B., Weissensee P., Kerman L.L., Tang L., Sandrasagra A. Eur. J. Pharmacol. 1996, 317:417.
5. Kalkman H.O., Matkovits-Gupta T., Alphs L., Gharabawi G. Eur. Neuropsychopharmacol. 1999, 9:282.
6. Fairweather D.B., Young F., Zaninelli R. Eur. Neuropsychopharmacol. 2002, 12:277.
7. Citrome L., Meng X., Hochfeld M. Schizophr. Res. 2011, 131:75.
8. Crabtree B.L., Montgomery J. Clin. Ther. 2011, 33:330.
9. Mutlib A.E., Strupczewski J.T. J. Chromatogr. B 1995, 669:237.
10. Subramanian N., Kalkman H.O. Prog. Neuropsychopharmacol. Biol. Psychiat. 2002, 26:553.
11. Mutlib A.E., Klein J.T. J. Pharmacol. Exp. Ther. 1998, 286:1285.
12. Sainati S.M., Hubbard J.W., Chi E., Grasing K., Brecher M.B. J. Clin. Pharmacol. 1995, 35:713.
13. Chhalotiya U.K., Bhatt K.K., Shah D.A., Patel J.R. ISRN Analytical Chemistry 2012 2012.
14. Lasser R.A., Guven A., Hourani J., Gharabawi M. Eur. Neuropsychopharmacol. 2001, 11:S293.
15. Vigneault P., Pilote S., Patoine D., Simard C., Drolet B. Can. J. Cardiol. 2011, 27:S157.
16. U.S. FDA, Guidance for Industry: Bioanalytical Method Validation, CDER, Rockville, MD, 2001.